Brief overview describing the disease entities, their similarities and differences here.
·          Asthma
·          Eosinophilia  >10
·          Neuropathy  (mononeuropathy or polyneuropathy)
·          Pulmonary  infiltration, non-fixed
·          Paranasal sinus  abnormality
·          Biopsy with  extravascular eosinophilic infiltration
Lanham’s  criteria, all of the following need to be present:
·          Asthma
·          Eosinophilia  peak of >1.5x109cell/L
·          Systemic<unk> , two or greater extra pulmonary sites
·          Abnormal  urinary sediment ( red cell casts or > 5 red blood cells per hpf)
·          Abnormal chest  radiography ( nodules, cavities, or fixed infiltrates)
·          Nasal discharge  or oral ulcers
·          Biopsy with  granulomatous inflammation
According  to the European League Against Rheumatism, Pediatric Rheumatology European  Society and Pediatric Rheumatology International Trials Organization three  out of the six criteria are established:
·          Histopathology  shows granuloma
·          Upper  respiratory tract involvement
·          Stenosis of  larynx, trachea and bronchioles
·          Pulmonary  involvement
·          Anti-neutrophil  cytoplasmic antibodies
·          glomerulonephritis
2 to 3 per million  persons; higher prevalence’s seen in Europeans.
Incidence:
0.5 to 6.8 per million  persons
Age:
Mean age 48 years;  incidence occurs in females between 1st decade to 7th  decade. Males are similarly as females.
Gender:
no sex predominance is  seen
Race:
Prevalence of the  disease is seen in both Asiatic and European populations; displaying equal  distribution.
Europe: 23.7 to 160 per  million persons. Prevalence in the United States: 3 per 100,000 persons.
Incidence:
Europe: 3 to 14.4 per  million persons
Children: 0.03 to 3.2  per 100,000 persons
Age:
Mean age 58 years;  incidence occurs in females during 7th decade and males in the 8th  decade. Commonly seen in middle aged and elderly patients. In children the  ages are 4 to 17 however, the disease is rarely seen.
Gender:
Males are more commonly  affected; the overall ratio is 1.2 to 1. However, the ratio is dependent upon  geographical location. In children females are commonly seen with the  disease.
Race:
Affects Caucasian race,  other races may be affected however the rates are lower.
1 to 3 per 100,000  persons.
Southern Sweden: 94 per  million persons
Incidence:
Spain: 11.6 per million  persons
United Kingdom: 5.9 per  million persons
United States: 3.6 per  millions persons
Norway: 2.7 per million  persons
*during the last 2  decades the rate of incidences have increased, which is attributed to the  availability of<unk>  testing.
Age:
seen during the 5th  and 6th decade of life
Gender:
Males are more commonly  affected than females; overall ratio is 1.8 to 1.
Race:
Typically seen in  patients of Asiatic and southern European descents.
Arthralgia,  myalgia, pyrexia, weight loss, asthma, nasal polys, allergic rhinitis,  sinusitis, otitis media, sensorineural hearing loss, asthenia
Eosinophilic phase:
Peripheral  eosinophilia, pulmonary infiltrates, ground glass opacities, thickening of  bronchial wall, endomyocardial infiltrates, arrhythmia, pericarditis,  abdominal pain
Vascular phase:
Pyrexia,  weight loss, fatigue, multiplex mononeuritis, cerebral infarcts, rapid  progressive glomerulonephritis, pauci-immune focal and segmental necrotizing  glomerulonephritis, palpable purpura and nodules, maculopapular erythema,
Livedo  reticularis, petechiae, ecchymoses
Malaise, pyrexia, weight loss,  arthralgia, cough, dyspnea, purpura, and abnormal urinary sediment
Renal  involvement:
Glomerulonephritis, hematuria,  elevated serum creatinine, edema, hypertension, red cell casts
Renal  inflammation (glomerulonephritis), weight loss, skin lesions, nerve damage,  pyrexia.
Renal involvement:
Hematuria,  proteinuria, red cell casts
Infarcts,  hemorrhage and scarring of affected organs
Pulmonary  artery occlusion
Patchy  consolidation (lower portion of lung)
Fibrosis,  ventricular hypertrophy of both ventricles, patchy myocardial scars, and  endocardial fibrosis
necrosis  of bone and cartilage
vascular  necrosis
Fibrinous  necrosis of lung
Intra-alveolar  hemosiderosis
Giant cell<unk>   with eosinophils
Interstitial and  perivascular necrotizing granulomas
Eosinophilic  lymphadenopathy
presence of  non-caseating granuloma
necrotizing<unk> 
at times varied  multinucleated giant cells
Crescent glomeruli
Minimal deposition of  immunoglobulins
Compliment in glomeruli  and renal vasculature
Myeloperoxidase  antigen 40% sensitivity
Proteinase  3 antigen <5% sensitivity
Myeloperoxidase  antigen 10% sensitivity
Proteinase  3 antigen 70-80% sensitivity
Myeloperoxidase  antigen 30% sensitivity
Proteinase  3 antigen 60% sensitivity
Light  microscopy: necrotizing and crescentic glomerulonephritis
Skin  biopsy: immunoglobulins and complement components
Renal  biopsy:
crescent  formation with focal necrosis
Lung  biopsy:
Alveolar  capillaritis
Nerve  biopsy:
Vascular  necrosis of small and medium sized vessels
Mild form
Glucocorticoid
Methotrexate
Azathioprine
Hydroxyurea
Mycophenolate
Severe form
Glucocorticoid +  cyclophosphamide
Second-line therapy:
IV immunoglobulins +  glucocorticoids + immunosuppressant in patients with flare-ups due to certain  medication or during pregnancy.
Maintenance:
Azathioprine
Methotrexate
Glucocorticoid
Cyclophosphamide
Rituximab
Maintenance:
Azathioprine
Methotrexate
Rituximab
Glucocorticoid +  cyclophosphamide
Severe form
Glucocorticoid +  immunosuppressant + plasmapheresis
Maintenance:
Myclophenolate mofetil
Methotrexate
ANCA associated vasculitis
Hypersensitivity vasculitis
Livedoid vasculitis
C3 glomerulopathy
Granulomatosis with polyangiitis laboratory findings
C4 glomerulopathy
Polyarteritis nodosa pathophysiology
Microscopic polyangiitis pathophysiology